Dr. Berrak Gümüşkaya Öcal

Current Appointments:

February 2021-Present: Professor of Pathology, Ankara Yildirim Beyazit University School of Medicine, Ankara

2019-Present: Ankara City Hospital


Genitourinary Surgical Pathology, Molecular Pathology
Sign out of in house cases and consultations, and consultations out of institution

Sign out of in house molecular pathology reports of solid tumors including ISH, PCR based, and NGS.

Education and Professional Experiences:

  • 1996-2003   Medical School of Ankara University, MD
  • 2004-2009   Resident,Pathology Department of Ankara Diskapi Training and Research Hospital
  • 2009-2011 Surgical Pathologist, Kars Government Hospital, Turkey
  • 2011-2013 PostDoctoral Fellow of Urologic Pathology, Johns Hopkins University, Department of Pathology, De Marzo Lab
  • 2013-2015 Assistant Professor of Department of Pathology, Ankara Yildirim Beyazit University School of Medicine
  • 2013-2014 Coordinator assistant of 3rd term Medical School, Ankara Yildirim Beyazit University School of Medicine
  • 2015-2017 Educational administrative accountant and Head of Department of Pathology, Ankara Yildirim Beyazit University School of Medicine
  • 2021 Professor of Department of Pathology, Ankara Yildirim Beyazit University School of Medicine

Publications of last 5 years

  1. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2015
  2. Active nano/microbilayer hemostatic agents for diabetic rat bleeding model. Journal of Biomedical Materials Research Part B: Applied Biomaterials 2017
  3. A Large Posteriorly Located Prostatic Mass Lesion Challenging the Robotic Surgeon: Prostate Leiomyoma. Journal of Endourology Case Reports 2017
  4. A Comparative Study of Receptor-Targeted Magnetosome and HSA-Coated Iron Oxide Nanoparticles as MRI Contrast-Enhancing Agent in Animal Cancer Model. Appl Biochem Biotechnol (2018)
  5. Prognostic significance of the programmed death ligand 1 expression in clear cell renal cell carcinoma and correlation with the tumor microenvironment and hypoxia-inducible factor expression. Diagnostic Pathology13, 60. 2018
  6. Diagnosing atypia of undetermined significance in thyroid fine needle aspiration samples using nuclear scoring, Annals of Diagnostic Pathology, Volume 41, 2019
  7. Autologous stem cell-derived chondrocyte implantation with bio-targeted microspheres for the treatment of osteochondral defects. Journal of orthopaedic surgery and research2019
  8. FDG Hepatic Superscan Due to Metastatic Infiltration of Prostate Cancer. Clin Nucl Med. 2020
  9. Use of Aspirin and Statins in Relation to Inflammation in Benign Prostate Tissue in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2020
  10. Multicenter Multireader Evaluation of an Artificial Intelligence-Based Attention Mapping System for the Detection of Prostate Cancer With Multiparametric MRI. AJR Am J Roentgenol. 2020
  11.  ‘No Residual Tumor’ Rate in Radical Cystectomy Specimens. J Urol Surg 2019
  12.  Robot Assisted Radical Cystectomy Outcomes in Micropapillary and Plasmacytoid Variants. Urol J. 2020
  13. The role of Multiparametric Magnetic Resonance Imaging to Detect the Extracapsular Extension in Robot Assisted Radical Prostatectomy. Bull Urooncol 2020


Award Winner Poster

 Johns Hopkins University School of Medicine Prostate Cancer Research Day, 1st prize of poster presentations ‘Assessing the order of critical alterations in prostate cancer development and progression by IHC: Further evidence that PTEN loss occurs subsequent to ERG gene fusion’, February 2012, Baltimore, USA

Invited Reviews Molecular Pathology of Head and Neck Cancers, Turkiye Klinikleri J Med Oncol-Special Topics 2018